Putative neuroprotective effects of caffeine in clinical trials. Concluding remarks
J Alzheimers Dis
.
2010:20 Suppl 1:S249-52.
doi: 10.3233/JAD-2010-01411.
Authors
Alexandre de Mendonça
1
,
Rodrigo A Cunha
Affiliation
1
Institute of Molecular Medicine and Faculty of Medicine, University of Lisbon, Portugal.
PMID:
20448306
DOI:
10.3233/JAD-2010-01411
No abstract available
Publication types
Editorial
MeSH terms
Alzheimer Disease / drug therapy*
Caffeine / therapeutic use*
Clinical Trials as Topic / methods*
Humans
Neuroprotective Agents / therapeutic use*
Substances
Neuroprotective Agents
Caffeine